News & Events
2005 Press Releases
Eidogen-Sertanty Launches DirectDesign Discovery Service
San Diego, CA (July 13, 2005) - Eidogen-Sertanty, Inc., a computational drug discovery solutions provider, today announced the launch of DirectDesign™, a collaborative, medicinal chemist friendly de novo drug design service that leverages the company's full suite of discovery informatics software and database products. The DirectDesign service offering complements the company's existing structural informatics and cheminformatics business by enabling customers to fully leverage Eidogen-Sertanty's complete suite of technology on a project-by-project basis.
"Since the merger of Eidogen and Sertanty in March 2005, we have demonstrated significant market acceptance with 12 software and database bookings and renewals spanning small, medium and large drug discovery organizations," said Dr. Steven Muskal, CEO of Eidogen-Sertanty. "Complementing our software and database offerings, we are excited to launch the DirectDesign service offering as an opportunity for our current and future customers to fully exploit the complete spectrum of our knowledge-driven discovery informatics capabilities on a collaborative basis."
The DirectDesign service facilitates the target-focused design of synthetically accessible, novel ligands. One key enabling technology of DirectDesign is the Chemical Intelligence Platform (ChIP), which enables rapid, efficient exploration of medicinally relevant and synthetically accessible chemical space focused around targets and chemistries of interest.
The other key enabling technology of DirectDesign is Eidogen-Sertanty's Target Informatics Platform (TIP™) and EVE® Target Analyzer. TIP is the first structural informatics platform of its kind, providing a pre-computed database of structural models, along with pre-computed binding site annotations and similarity relationships at the structural and binding site level. EVE enables advanced comparative analysis of binding sites and computational assessments of compound activity based on state-of-the-art comparative binding mode analysis capabilities.
The Eidogen-Sertanty suite of knowledge-based structural informatics and cheminformatics technology solutions were designed to fit the workflows of computational scientists, making their target- and ligand-based discovery informatics activities more efficient and more effective.
"Our fully integrated software solutions enable a complete knowledge-driven discovery pipeline, efficiently driving the process from target prioritization to selective lead identification," said Dr. Derek Debe, Chief Scientific Officer. "With our software, databases, and DirectDesign's synthesis-driven de novo drug design approach, we are confident that we can help our pharmaceutical partners decrease the time and expense from target to IND."
For more information, please contact:
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.